The event S:Apple Watch was officially released at Apple Inc's 2015 spring product conference at 1: 00 a.m. on March 10, Beijing time, accepted the reservation on April 10, and officially went on sale on April 24.
Main points of investment:
Apple watch will build consumers' overall understanding of smart wearable devices, which is good for the ihealth series that has fully docked with Apple Inc's HealthKit platform, and the subsequent sales space will be activated. Apple watch has a "health and exercise" module, the self-table itself can only collect human exercise data and heart rate data, for medical and health indicators such as blood pressure, blood sugar, blood oxygen and other indicators still need the help of third-party equipment and supporting APP to complete. All their own and third-party data will be converged and shared on the "healthy" APP (that is, the HealthKit platform) on iPhone. Therefore, the hot sale of apple watch will activate the volume of third-party medical wearable devices, the company's independent brand ihealth series as the largest domestic mobile medical product series, and all the products have completed docking with the HealthKit platform, sales are expected to accelerate.
Ihealth series revenue is expected to double in 14 years, and ihealth's share of revenue is expected to increase to 50 per cent in 16 years. Among them, 14 years overseas ihealth series growth rate of more than 50%, domestic ihealth series began to sell in July 14, sales are expected to be nearly 20 million, most of the domestic income from cooperation with XIAOMI's first product-intelligent cloud sphygmomanometer BP3, is expected to launch the second cooperative product in 15 years. As more products are sold on the domestic market, the domestic market is growing rapidly.
In the future, the company's development and application of health big data will be interesting. Connecting with mobile intelligent terminals is just the beginning. The company has completed the collection, storage and preliminary analysis of users' health information. In the future, it is hoped that with the help of cloud technology, users' health status will be monitored after massive user data are stored, managed and analyzed, and corresponding diagnosis and treatment suggestions will be provided to users in a timely manner.
Maintain the "highly recommended" rating. At present, the company's performance is affected by the continuous high market development, R & D and management costs at the initial stage of promotion, and the short-term performance is not ideal. 14 years because of the investment income of Sun Company, the performance pressure is still great in 15 years. However, considering that the company is a forerunner in the mobile medical industry, the industry is expected to grow explosively, the company's management, R & D and marketing team are excellent, and the company is optimistic about the company's future health big data service and health management business. Raise the target price to 40.32 yuan, corresponding to the market value of 15 billion yuan, it is recommended to continue to pay attention.
Risk hint: the risk that the promotion of ihealth series is lower than expected and the risk of intensified competition among domestic enterprises
